Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:3
članak: 1 od 12  
Back povratak na rezultate
Vojnosanitetski pregled
2012, vol. 69, br. 12, str. 1067-1075
jezik rada: engleski
vrsta rada: originalan članak
doi:10.2298/VSP111114028K
Fluoksetin ne remeti motornu funkciju kod bolesnika sa Parkinsonovom bolešću - korelacija raspoloženja i motorne funkcije sa koncentracijom fluoksetina/norfluoksetina u plazmi
aCCS, Clinic of Neurology, Belgrade
bUniverzitet u Beogradu, Medicinski fakultet, Institut za farmakologiju, kliničku farmakologiju i toksikologiju
cPolicijska akademija
dMedicines and Medical Devices Agency of Serbia, Belgrade
eUniverzitet u Beogradu, Farmaceutski fakultet, Institut za farmakokinetiku

Projekat

Motorni i nemotorni simptomi parkinsonizma: kliničke, morfološke i molekularno-genetičke korelacije (MPNTR - 175090)

Sažetak

Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja serotonina su antidepresivi koji se najčešće koriste u lečenju obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja bio je da se proceni uticaj fluoksetina (Flu) na motorne funkcije bolesnika sa PB. Metode. U ovom prospektivnom, kontrolisanom, otvorenom kliničkom ispitivanju, 18 bolesnika sa PB i blagom depresijom [10 ≤ Hamiltonova skala za depresiju (10 ≤ HDRS) ≤ 23)], bez demencije [(25 ≤ Mini mental test (MMSE)] lečeni su primenom Flu. Procenjivana su dejstva kako pojedinačne, tako i ponovljene doze Flu od prvog do osamdesetog dana. Plazma koncentracije Flu i norfluoksetina (NORFlu) korelisane su sa rezultatima odeđenih testova za motorne funkcije: skala za procenu težine PB (UPDRS), test spretnosti kucanja (FTT) i Purdue pegboard Test PPT). Izraženost PD, depresije i demencije procenjivane su korišćenjem standardnih testova [(test dnevnih aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS, MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu postignuto je 18. dana lečenja. Takav plato u koncentraciji Flu/NORFlu bio je praćen značajnim poboljšanjem rezultata, kako testova za depresiju, tako i za izraženost PB (HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati FTT-a i PPT-a bili su u porastu do 18. dana, sa blagim fluktuacijama oko platoa. Optimalna motorna postignuća zabeležena su pri koncentraciji Flu od oko 60-110 μg/L. Zaključak. Flu (20 mg/dan) značajno redukuje depresiju kod bolesnika sa PB i ne remeti motorne funkcije. S obzirom na mogući placebo efekat u istraživanjima sa PB i depresijom, neophodna su obimnija, prospektivna, randomizovana, placebo- kontrolisana klinička ispitivanja.

Ključne reči

Reference

*** (2001) Extrapyramidal effects of SSRI antidepressants. Prescrire Int, 10(54); 118-9
Albin, R.L., Koeppe, R.A., Bohnen, N.I., Wernette, K., Kilbourn, M.A., Frey, K.A. (2008) Spared caudal brainstem SERT binding in early Parkinson's disease. Journal of cerebral blood flow and metabolism, 28(3): 441-4
Alex, K.D., Pehek, E.A. (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology & therapeutics, 113(2): 296-320
Allain, H., Schuck, S., Mauduit, N. (2000) Depression in Parkinson's disease. BMJ (Clinical research ed.), 320(7245): 1287-8
Altamura, A.C., Moro, A.R., Percudani, M. (1994) Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet, 26(3): 201-14
Arbouw, M.E.L., Movig, K.L.L., Neef, C., Guchelaar, H., Egberts, T.C.G. (2007) Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. European journal of clinical pharmacology, 63(2): 181-7
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. Journal of the neurological sciences, 20(4): 415-55
Boileau, I., Warsh, J.J., Guttman, M., Saint-Cyr, J.A., McCluskey, T., Rusjan, P., Houle, S., Wilson, A.A., Meyer, J.H., Kish, S.J. (2008) Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB. Movement disorders, 23(12): 1776-80
Bolo, N.R., Hodé, Y., Nédélec, J.F., Lainé, E., Wagner, G., Macher, J.P. (2000) Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology, 23(4): 428-38
Braak, H., del Tredici, K. (2008) Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology, 70(20): 1916-25
Braak, H., del Tredici, K., Rub, U., de Vos, R.A.I., Jansen, S.E.N.H., Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24(2): 197-211
Caley, C.F., Friedman, J.H. (1992) Does fluoxetine exacerbate Parkinson's disease?. Journal of clinical psychiatry, 53(8): 278-82
Ceravolo, R., Nuti, A., Piccinni, A., Dell'Agnello, G., Bellini, G., Gambaccini, G., Dell'Osso, L., Murri, L., Bonuccelli, U. (2000) Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology, 55(8): 1216-8
Charlier, C., Pinto, E., Ansseau, M., Plomteux, G. (2000) Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine. Human psychopharmacology, 15(6): 453-459
Chung, K.A., Carlson, N.E., Nutt, J.G. (2005) Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology, 64(10): 1797-8
D'Amato, R.J., Zweig, R.M., Whitehouse, P.J., Wenk, G.L., Singer, H.S., Mayeux, R., Price, D.L., Snyder, S.H. (1987) Aminergic systems in Alzheimer's disease and Parkinson's disease. Annals of neurology, 22(2): 229-36
dell'Agnello G., Ceravolo, R., Nuti, A., Bellini, G., Piccinni, A., d'Avino C., dell'Osso L., Bonuccelli, U. (2001) SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study. Clinical neuropharmacology, 24(4): 221-7
di Matteo, V., de Blasi, A., di Giulio, C., Esposito, E. (2001) Role of 5-HT(2C) receptors in the control of central dopamine function. Trends in pharmacological sciences, 22(5): 229-32
Drevets, W.C., Thase, M.E., Moses-Kolko, E.L., Price, J., Frank, E., Kupfer, D.J., Mathis, C. (2007) Serotonin-1A receptor imaging in recurrent depression: Replication and literature review. Nuclear medicine and biology, 34(7): 865-77
Ehrt, U., Brønnick, K., Leentjens, A.F.G., Larsen, J.P., Aarsland, D. (2006) Depressive symptom profile in Parkinson's disease: A comparison with depression in elderly patients without Parkinson's disease. International journal of geriatric psychiatry, 21(3): 252-8
Fahn, S., Elton, R.L., UPDRS Development Committee (1987) The unified Parkinson’s disease rating scale. u: Fahn S, Marsden CD, Calne DB, Goldestein M [ur.] Recent Developments in Parkinson s Disease, Florham Park, NJ: Macmillan Healthcare Information, p. 153-163
Fahn, S., Libsch, L.R., Cutler, R.W. (1971) Monoamines in the human neostriatum: Topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. Journal of the neurological sciences, 14(4): 427-55
Folstein, M.F., Folstein, S.E., McHugh, P.R. (1975) 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12(3): 189-98
Fox, S.H., Moser, B., Brotchie, J.M. (1998) Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental neurology, 151(1): 35-49
Fox, S.H., Brotchie, J.M. (2000) 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. European journal of pharmacology, 398(1): 59-64
Fox, S.H., Chuang, R., Brotchie, J.M. (2009) Serotonin and Parkinson's disease: On movement, mood, and madness. Movement disorders, 24(9): 1255-66
Goetz, C.G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G.T., Counsell, C., Giladi, N., Holloway, R.G., Moore, C.G., Wenning, G.K., Yahr, M.D., Seidl, L. (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Movement disorders, 19(9): 1020-8
Gony, M., Lapeyre-Mestre, M., Montastruc, J. (2003) Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: A pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clinical neuropharmacology, 26(3): 142-5
Groenewegen, H.J., Uylings, H.B. (2000) The prefrontal cortex and the integration of sensory, limbic and autonomic information. Progress in brain research, 126: 3-28
Guttman, M., Boileau, I., Warsh, J., Saint-Cyr, J.A., Ginovart, N., McCluskey, T., Houle, S., Wilson, A., Mundo, E., Rusjan, P., Meyer, J., Kish, S.J. (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. European journal of neurology, 14(5): 523-8
Halliday, G.M., Li, Y.W., Blumbergs, P.C., Joh, T.H., Cotton, R.G., Howe, P.R., Blessing, W.W., Geffen, L.B. (1990) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Annals of neurology, 27(4): 373-85
Hamilton, M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry, 23: 56-62
Hauser, R.A., Zesiewicz, T.A. (1997) Sertraline for the treatment of depression in Parkinson's disease. Movement disorders, 12(5): 756-9
Helmich, R.C., de Lange, F.P., Bloem, B.R., Toni, I. (2007) Cerebral compensation during motor imagery in Parkinson's disease. Neuropsychologia, 45(10): 2201-15
Helmich, R.C., Aarts, E., de Lange, F.P., Bloem, B.R., Toni, I. (2009) Increased dependence of action selection on recent motor history in Parkinson's disease. Journal of neuroscience, 29(19): 6105-13
Hesse, S., Barthel, H., Schwarz, J., Sabri, O., Müller, U. (2004) Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neuroscience and biobehavioral reviews, 28(6): 547-63
Hoehn, M.M., Yahr, M.D. (1967) Parkinsonism: Onset, progression and mortality. Neurology, 17(5): 427-42
Hoyer, D., Pazos, A., Probst, A., Palacios, J.M. (1986) Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain research, 376(1): 97-107
Ilic, T.V., Korchounov, A., Ziemann, U. (2002) Complex modulation of human motor cortex excitability by the specific serotonin re-uptake inhibitor sertraline. Neuroscience letters, 319(2): 116-20
Invernizzi, R.W., Pierucci, M., Calcagno, E., di Giovanni, G., di Matteo, V., Benigno, A., Esposito, E. (2007) Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: A combined in vivo electrophysiological and neurochemical study. Neuroscience, 144(4): 1523-35
Jankovic, J., Tolosa, E. (2007) Depression in parkinson's disease and movement disorders. Philadelphia: Lippincott Williams and Wilkins, 5th ed
Kerenyi, L., Ricaurte, G.A., Schretlen, D.J., McCann, U., Varga, J., Mathews, W.B., Ravert, H.T., Dannals, R.F., Hilton, J., Wong, D.F., Szabo, Z. (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Archives of neurology, 60(9): 1223-9
Kish, S.J., Tong, J., Hornykiewicz, O., Rajput, A., Chang, L.J., Guttman, M., i dr. (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain, 131 (1): 120-131
Kostić, V.S., Filipović, S., Lečić, D., Momčilović, D., Sokić, D., Šternić, N. (1994) Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry, 57(10): 1265-7
Kostić, V.S., Lečić, D., Filipović, S., Stojanović, M. (1995) Depression and Parkinson’s disease. Psychiatriki, 6: 125-35
Kostić, V.S., Djuricić, B.M., Covicković-Sternić, N., Bumbasirević, L., Nikolić, M., Mrsulja, B.B. (1987) Depression and Parkinson's disease: Possible role of serotonergic mechanisms. Journal of neurology, 234(2): 94-6
Kostić, V.S., Stefanova, E., Dragašević, N., Potrebić, A. (2003) Diagnosis and treatment of depression in Parkinson's disease. u: Bedard M.A., Agid Y., Chouinard S. [ur.] Mental and Behavioral Dysfunction in Movement Disorders, Totowa, NJ: Humana Press, str. 351-368
Kuopio, A.M., Marttila, R.J., Helenius, H., Toivonen, M., Rinne, U.K. (2000) The quality of life in Parkinson's disease. Movement disorders, 15(2): 216-23
Laasonen-Balk, T., Viinamäki, H., Kuikka, J.T., Husso-Saastamoinen, M., Lehtonen, J., Tiihonen, J. (2004) 123I-beta-CIT binding and recovery from depression. A six-month follow-up study. European archives of psychiatry and clinical neuroscience, 254(3): 152-5
Leo, R.J. (1996) Movement disorders associated with the serotonin selective reuptake inhibitors. Journal of clinical psychiatry, 57(10): 449-54
Lezak, D.M. (1983) Neuropsychological assessment. New York: Oxford university
Machado, M., Iskedjian, M., Ruiz, I., Einarson, T.R. (2006) Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials. Current medical research and opinion, 22(9): 1825-37
Mayeux, R., Stern, Y., Williams, J.B., Cote, L., Frantz, A., Dyrenfurth, I. (1986) Clinical and biochemical features of depression in Parkinson's disease. American journal of psychiatry, 143(6): 756-9
Meara, R.J., Bhowmick, B.K., Hobson, J.P. (1996) An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson's disease. Journal of Serotonin Research, 2(4), 243-249
Menza, M., Marin, H., Kaufman, K., Mark, M., Lauritano, M. (2004) Citalopram treatment of depression in Parkinson's disease: The impact on anxiety, disability, and cognition. Journal of neuropsychiatry and clinical neurosciences, 16(3): 315-9
Meyer, J.H., Wilson, A.A., Sagrati, S., Hussey, D., Carella, A., Potter, W.Z., Ginovart, N., Spencer, E.P., Cheok, A., Houle, S. (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. American journal of psychiatry, 161(5): 826-35
Miyasaki, J.M., Shannon, K., Voon, V., Ravina, B., Kleiner-Fisman, G., Anderson, K., Shulman, L.M., Gronseth, G., Weiner, W.J. (2006) Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 66(7): 996-1002
Ni, Y.G., Miledi, R. (1997) Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA, 94(5): 2036-40
Nierenberg, A.A., Farabaugh, A.H., Alpert, J.E., Gordon, J., Worthington, J.J., Rosenbaum, J.F., Fava, M. (2000) Timing of onset of antidepressant response with fluoxetine treatment. American journal of psychiatry, 157(9): 1423-8
Oertel, W.H., Hoglinger, G.U., Caraceni, T. (2001) Depression in Parkinson's disease: An update. u: Calne D., Calne S. [ur.] Parkinson's disease: Advances in neurology: Parkinson's disease, Philadelphia: Lippincott Wiliams and Wikins, p. 373
Okun, M.S., Watts, R.L. (2002) Depression associated with Parkinson's disease: Clinical features and treatment. Neurology, 58(4 Suppl 1): S63-70
Paulus, W., Jellinger, K. (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. Journal of neuropathology and experimental neurology, 50(6): 743-55
Politis, M., Wu, K., Loane, C., Turkheimer, F.E., Molloy, S., Brooks, D.J., Piccini, P. (2010) Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology, 75(21): 1920-7
Rampello, L., Chiechio, S., Raffaele, R., Vecchio, I., Nicoletti, F. (2002) The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clinical neuropharmacology, 25(1): 21-4
Richard, I.H., Kurlan, R. (1997) A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology, 49(4): 1168-70
Richard, I.H., Maughn, A., Kurlan, R. (1999) Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Movement disorders, 14(1): 155-7
Rick, C.E., Stanford, I.M., Lacey, M.G. (1997) Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: Evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience, 69(3), 903-13
Ringendahl, H. (2002) Factor structure, normative data and retest-reliability of a test of fine motor functions in patients with idiopathic Parkinson's disease. Journal of clinical and experimental neuropsychology, 24(4): 491-502
Ritter, J.L., Alexander, B. (1997) Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Annals of clinical psychiatry, 9(1): 7-13
Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., Agid, Y. (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain research, 275(2): 321-8
Seppi, K. (2011) Abnormal serotonergic neurotransmission contributes to the pathophysiology of depression in PD. Movement Disorders, 26(3): 379-379
Shannak, K., Rajput, A., Rozdilsky, B., Kish, S., Gilbert, J., Hornykiewicz, O. (1994) Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: Observations in Parkinson's disease and normal subjects. Brain research, 639(1): 33-41
Shimoyama, I., Ninchoji, T., Uemura, K. (1990) The finger-tapping test. A quantitative analysis. Archives of neurology, 47(6): 681-4
Suzuki, K., Okada, K., Wakuda, T., Shinmura, C., Kameno, Y., Iwata, K., Takahashi, T., Suda, S., Matsuzaki, H., Iwata, Y., Hashimoto, K., Mori, N. (2010) Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: Reversal by fluoxetine. PloS one, 5(2): e9260
Tauscher, J., Pirker, W., de Zwaan, M., Asenbaum, S., Brücke, T., Kasper, S. (1999) In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. European neuropsychopharmacology, 9(1-2): 177-9
Taylor, A., Saint-Cyr, J.A., Lang, A.E., Kenny, F.T. (1986) Parkinson's disease and depression. A critical re-evaluation. Brain, 109(2): 279-292
Tesei, S., Antonini, A., Canesi, M., Zecchinelli, A., Mariani, C.B., Pezzoli, G. (2000) Tolerability of paroxetine in Parkinson's disease: A prospective study. Movement disorders, 15(5): 986-9
Tom, T., Cummings, J.L. (1998) Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs & aging, 12(1): 55-74
Vajda, F.J.E., Solinas, C. (2005) Current approaches to management of depression in Parkinson's Disease. Journal of clinical neuroscience, 12(7): 739-43
van de Vijver, D.A.M.C., Roos, R.A.C., Jansen, P.A.F., Porsius, A.J., de Boer, A. (2002) Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. British journal of clinical pharmacology, 54(2): 168-70
Veazey, C., Aki, S.O.E., Cook, K.F., Lai, E.C., Kunik, M.E. (2005) Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci, 17(3): 310-23
Walter, U., Hoeppner, J., Prudente-Morrissey, L., Horowski, S., Herpertz, S.C., Benecke, R. (2007) Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain, 130(7): 1799-1807
Weintraub, D., Taraborelli, D., Morales, K.H., Duda, J.E., Katz, I.R., Stern, M.B. (2006) Escitalopram for major depression in Parkinson's disease: An open-label, flexible-dosage study. Journal of neuropsychiatry and clinical neurosciences, 18(3): 377-83
Zesiewicz, T.A., Gold, M., Chari, G., Hauser, R.A. (1999) Current issues in depression in Parkinson's disease. American journal of geriatric psychiatry, 7(2): 110-8